A pilot study of cdc6 as a biomarker for circulating tumor cells in patients with lung cancer.
A549 Cells
Adult
Aged
Aged, 80 and over
Biomarkers, Tumor
/ genetics
Case-Control Studies
Cell Cycle Proteins
/ genetics
Female
Fetal Blood
/ cytology
Gene Expression Regulation, Neoplastic
Humans
In Situ Hybridization
/ methods
Lung Diseases
/ genetics
Lung Neoplasms
/ genetics
Male
Middle Aged
Neoplastic Cells, Circulating
/ metabolism
Nuclear Proteins
/ genetics
Pilot Projects
Proto-Oncogene Mas
cdc6
lung cancer
peripheral blood mononuclear cell
proliferating cell
Journal
Journal of clinical laboratory analysis
ISSN: 1098-2825
Titre abrégé: J Clin Lab Anal
Pays: United States
ID NLM: 8801384
Informations de publication
Date de publication:
Jun 2020
Jun 2020
Historique:
received:
18
10
2019
revised:
20
01
2020
accepted:
21
01
2020
pubmed:
7
4
2020
medline:
2
6
2021
entrez:
7
4
2020
Statut:
ppublish
Résumé
Cell division cycle 6 (cdc6) is a key factor of DNA replication initiation license system and a proto-oncogene. It has been detected in some tumor tissues to aid cancer diagnosis in many research projects. However, it remains unclear that if cdc6 could be detected in the peripheral blood, just like liquid biopsy, in solid tumor patients. The aim of this study is to investigate the possibility of cdc6 as a biomarker for circulating tumor cells in patients with lung cancer. We first detected the expression of cdc6 in peripheral blood mononuclear cells (PBMCs) and tumor cells by in situ hybridization with cdc6 RNA probe. Then, we examined the expression of cdc6 in PBMCs from health individual, mononuclear cells from cord blood, or A549 cell line by RT-qPCR. Furthermore, we used RT-qPCR to test the cdc6 expression in PBMCs from tumor patients (test group) and non-tumor individuals as a control group. Chi-square test with Fisher's exact test was used to analyze the statistical significance of the difference. P < .05 is considered as statistically significant difference. When compared the cdc6 expression in cells from difference sources, we found that A549 tumor cell line had the strongest expression of cdc6, samples from cord blood showed the least expression level, indicating the detection strategy of RT-qPCR is reasonable. Using this method, we studied whether cdc6 in Peripheral blood could be detected as a biomarker by examining cdc6 expression from PBMCs of patients with lung cancer. We found 20% of patients with lung cancer were cdc6 positive in PBMCs, whereas only 4.26% was found positive in the control group (P = .039, P < .05). Cell division cycle 6 has a potential to be used as a circulating tumor cell biomarker for lung cancer. Further study in clinical application is still broad needed.
Sections du résumé
BACKGROUND
BACKGROUND
Cell division cycle 6 (cdc6) is a key factor of DNA replication initiation license system and a proto-oncogene. It has been detected in some tumor tissues to aid cancer diagnosis in many research projects. However, it remains unclear that if cdc6 could be detected in the peripheral blood, just like liquid biopsy, in solid tumor patients. The aim of this study is to investigate the possibility of cdc6 as a biomarker for circulating tumor cells in patients with lung cancer.
METHODS
METHODS
We first detected the expression of cdc6 in peripheral blood mononuclear cells (PBMCs) and tumor cells by in situ hybridization with cdc6 RNA probe. Then, we examined the expression of cdc6 in PBMCs from health individual, mononuclear cells from cord blood, or A549 cell line by RT-qPCR. Furthermore, we used RT-qPCR to test the cdc6 expression in PBMCs from tumor patients (test group) and non-tumor individuals as a control group. Chi-square test with Fisher's exact test was used to analyze the statistical significance of the difference. P < .05 is considered as statistically significant difference.
RESULTS
RESULTS
When compared the cdc6 expression in cells from difference sources, we found that A549 tumor cell line had the strongest expression of cdc6, samples from cord blood showed the least expression level, indicating the detection strategy of RT-qPCR is reasonable. Using this method, we studied whether cdc6 in Peripheral blood could be detected as a biomarker by examining cdc6 expression from PBMCs of patients with lung cancer. We found 20% of patients with lung cancer were cdc6 positive in PBMCs, whereas only 4.26% was found positive in the control group (P = .039, P < .05).
CONCLUSION
CONCLUSIONS
Cell division cycle 6 has a potential to be used as a circulating tumor cell biomarker for lung cancer. Further study in clinical application is still broad needed.
Identifiants
pubmed: 32249466
doi: 10.1002/jcla.23245
pmc: PMC7307357
doi:
Substances chimiques
Biomarkers, Tumor
0
CDC6 protein, human
0
Cell Cycle Proteins
0
MAS1 protein, human
0
Nuclear Proteins
0
Proto-Oncogene Mas
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e23245Subventions
Organisme : guang an men hospital, China Academy of Chinese Medical Sciences
ID : GAMH2003S65.
Informations de copyright
© 2020 The Authors. Journal of Clinical Laboratory Analysis Published by Wiley Periodicals, Inc.
Références
Curr Med Chem. 2012;19(22):3689-700
pubmed: 22680928
Proc Natl Acad Sci U S A. 1997 Jan 7;94(1):142-7
pubmed: 8990175
Cell. 2011 Oct 14;147(2):275-92
pubmed: 22000009
Interface Focus. 2014 Jun 6;4(3):20130074
pubmed: 24904737
Adv Exp Med Biol. 2017;994:1-41
pubmed: 28560666
J Clin Lab Anal. 2020 Jun;34(6):e23245
pubmed: 32249466
Front Med. 2017 Dec;11(4):522-527
pubmed: 28744793
Cancer Genomics Proteomics. 2012 Sep-Oct;9(5):311-20
pubmed: 22990110
Lancet Oncol. 2014 Apr;15(4):406-14
pubmed: 24636208
Nat Med. 2006 Aug;12(8):895-904
pubmed: 16892035
Transcription. 2012 May-Jun;3(3):124-9
pubmed: 22771947
Transl Res. 2017 Jul;185:58-84.e15
pubmed: 28506696
Cell. 2006 Nov 17;127(4):679-95
pubmed: 17110329
Nat Rev Cancer. 2008 May;8(5):329-40
pubmed: 18404148
Transl Lung Cancer Res. 2017 Aug;6(4):473-485
pubmed: 28904890
Asian Pac J Cancer Prev. 2018 Jan 27;19(1):141-148
pubmed: 29373905
Exp Cell Res. 2005 Sep 10;309(1):56-67
pubmed: 16005865
Gan To Kagaku Ryoho. 2001 Jun;28(6):769-75
pubmed: 11432343
Int J Clin Oncol. 2017 Jun;22(3):421-430
pubmed: 28238187
Oncol Rep. 2018 Mar;39(3):929-938
pubmed: 29328493
Asian Pac J Cancer Prev. ;18(11):3041-3047
pubmed: 29172277
Clin Biochem. 2016 Jul;49(10-11):787-91
pubmed: 26968109
Mol Oncol. 2016 Mar;10(3):408-17
pubmed: 26899533
J Hematol Oncol. 2017 May 4;10(1):100
pubmed: 28472989
Carcinogenesis. 2008 Feb;29(2):237-43
pubmed: 18048387
Pharmacogenomics J. 2018 Jan;18(1):29-34
pubmed: 27503579